Psoriasis
Conditions
Brief summary
Rationale: * Psoriasis is a chronic immune-mediated inflammatory skin disorder where T cells play a fundamental role in its pathogenesis. * Low molecular weight heparin has been reported to exert immunomodulatory effect at small doses through inhibition of T cells heparinase enzyme. * Low molecular weight heparin may have promising results for treatment of psoriasis. Research question: * Can low molecular weight heparin be used safely for treatment of psoriasis with good outcome? * Is enoxaparin inhibitory effect on T cell heparinase enzyme responsible for its beneficial effect? Hypothesis: * Low molecular weight heparin can achieve good results when used at small doses for treatment of psoriasis. * Heparin can exert immunomodulatory effect in psoriasis through inhibition of T cell heparinase enzyme. AIM OF WORK -The aim of this work is to assess the possible clinical efficacy and safety of low-dose enoxaparin in the treatment of psoriasis and to detect if inhibition of heparinase enzyme might account for its beneficial therapeutic effect. Objectives: * To evaluate safety and efficacy of low molecular weight heparin at small dose for treatment of psoriasis. * Contribute to the ongoing efforts to optimize psoriasis management and improve the lives of individuals affected by this chronic condition.
Interventions
Selected patients will receive subcutaneous low dose enoxaparin once a week for 6 weeks.The level of serum heparinase enzyme will be measured before and after treatment
Sponsors
Zagazig University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with plaque psoriasis, who met the following criteria will be enrolled. 1. Age 18 and above. 2. No systemic (oral, parenteral, photobiological) treatment for psoriasis within the last 2 months. 3. No topical treatment for psoriasis within the last 2 weeks.
Exclusion criteria
* 1\. Pregnancy or lactation. 2. Hypersensitivity to heparin and heparin derivatives and a history of heparin-induced thrombocytopenia. 3\. History of bleeding diathesis, uncontrolled hypertension, cerebrovascular accident, peptic ulcer, liver disease and/or abnormal liver function tests or abnormal kidney function tests. 4\. History of major surgery within the last 3 months. 5. A family history of bleeding diathesis, or cerebrovascular accident. 6. Concomitant use of oral anticoagulants, acetylsalicylic acid, or other nonsteroidal anti-inflammatory drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Psoriatic Area and Severity Index score | weekly for 6 weeks and at follow up period of 6 weeks | The studied patients will be clinically evaluated weekly for 6 weeks and at follow up period; biweekly for 6 weeks |
Contacts
Primary ContactNourhan Anis
Outcome results
None listed